EF Hutton Reiterates Buy on Bicycle Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $50 price target.
August 04, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on Bicycle Therapeutics and maintained a $50 price target, indicating positive sentiment towards the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and maintenance of a $50 price target by EF Hutton indicates a positive outlook for Bicycle Therapeutics, which could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100